We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Mary A. Millner
Mary A. Millner
Products
PRODUCTS
Pinnacle Labs of Tennessee, LLC
Mary A. Millner
Price:
$117.00
View
Artivion, Inc.
Mary A. Millner
and
Inga M. Warr
Price:
$117.00
View
MRP, LLC dba Aquabiliti
Mary A. Millner
and
Jamie P. Webb
Price:
$117.00
View
Smith & Nephew, Inc.
Mary A. Millner
Price:
$117.00
View
B. Braun Medical, Inc.
Nakesha J. Jackson
,
Mary A. Millner
, and
Saundrea A. Munroe
Price:
$117.00
View
Wright Medical Technology, Inc.
Mary A. Millner
and
Javelle P. Spann
Price:
$117.00
View
Amplion Clinical Communications, Inc.
Nikki S. Bryant
and
Mary A. Millner
Price:
$117.00
View
Permobil, Inc.
Nikki S. Bryant
and
Mary A. Millner
Price:
$117.00
View
Mid South Precision, Inc.
Mary A. Millner
Price:
$117.00
View
Access Dental Lab, LLC
Mary A. Millner
and
Joseph J. Stanek
Price:
$117.00
View
View All Products by Mary A. Millner
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
